Tissue Elasticity as a Diagnostic Marker of Molecular Mutations in Morphologically Heterogeneous Colorectal Cancer
Anton A. Plekhanov,Dmitry S. Kozlov,Anastasia A. Shepeleva,Elena B. Kiseleva,Liubov E. Shimolina,Irina N. Druzhkova,Maria A. Plekhanova,Maria M. Karabut,Ekaterina V. Gubarkova,Alena I. Gavrina,Dmitry P. Krylov,Alexander A. Sovetsky,Sergey V. Gamayunov,Daria S. Kuznetsova,Vladimir Y. Zaitsev,Marina A. Sirotkina,Natalia D. Gladkova
DOI: https://doi.org/10.3390/ijms25105337
IF: 5.6
2024-05-15
International Journal of Molecular Sciences
Abstract:The presence of molecular mutations in colorectal cancer (CRC) is a decisive factor in selecting the most effective first-line therapy. However, molecular analysis is routinely performed only in a limited number of patients with remote metastases. We propose to use tissue stiffness as a marker of the presence of molecular mutations in CRC samples. For this purpose, we applied compression optical coherence elastography (C-OCE) to calculate stiffness values in regions corresponding to specific CRC morphological patterns (n = 54). In parallel to estimating stiffness, molecular analysis from the same zones was performed to establish their relationships. As a result, a high correlation between the presence of KRAS/NRAS/BRAF driver mutations and high stiffness values was revealed regardless of CRC morphological pattern type. Further, we proposed threshold stiffness values for label-free targeted detection of molecular alterations in CRC tissues: for KRAS, NRAS, or BRAF driver mutation—above 803 kPa (sensitivity—91%; specificity—80%; diagnostic accuracy—85%), and only for KRAS driver mutation—above 850 kPa (sensitivity—90%; specificity—88%; diagnostic accuracy—89%). To conclude, C-OCE estimation of tissue stiffness can be used as a clinical diagnostic tool for preliminary screening of genetic burden in CRC tissues.
biochemistry & molecular biology,chemistry, multidisciplinary